Truist Securities Maintains Buy on Boston Scientific, Raises Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reaffirmed a Buy rating on Boston Scientific (NYSE:BSX) and increased the price target from $59 to $66.
December 22, 2023 | 2:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Richard Newitter has maintained a Buy rating on Boston Scientific and raised the price target from $59 to $66, indicating a positive outlook on the stock.
The increase in price target by Truist Securities suggests a bullish outlook on Boston Scientific, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100